Target intelligence / Profile preview

Transmembrane emp24 domain-containing protein 5 (TMED5)

Target
TMED5
Molecular classification
Other (emp24/p24 family protein), Vesicular trafficking protein, Integral membrane protein, GOLD domain superfamily
01

Overview

Transmembrane emp24 domain-containing protein 5 (TMED5) is a member of the p24 protein family involved in the early secretory pathway within cells. TMED5 is an integral membrane protein located mainly in the cis-Golgi network, the endoplasmic reticulum exit sites, and the ER-Golgi intermediate compartment. Structurally, TMED5 contains a GOLD domain (for Golgi dynamics), a coiled-coil domain, a single transmembrane region, and a short cytoplasmic tail that interacts with COPI and COPII coat protein complexes, facilitating the selection of cargo and vesicle formation during protein trafficking. TMED5 is essential for the maintenance of the Golgi apparatus and protein trafficking between the ER and Golgi. Biologically, TMED5 is implicated in cell cycle regulation, apoptosis, and autophagy, through involvement in signaling pathways such as mTOR and TGF-β. In cancer, notably hepatocellular carcinoma and cervical cancer, TMED5 is often overexpressed and associated with worse outcomes and tumor progression; knockdown studies have shown suppressed proliferation, migration, invasion, and enhanced apoptosis. TMED5 is under investigation as a potential cancer therapeutic target and biomarker, but no clinically approved drugs currently target this protein

Other names
TMED5Transmembrane p24 trafficking protein 5p24 family protein gamma-2p24gamma2p24g2CGI-100p28transmembrane emp24 protein transport domain containing 5
02

Mechanism of action

None currently known; experimental silencing with siRNA has shown inhibition of proliferation, migration, and invasion of cancer cells

03

Biological functions

Golgi apparatus organizationEndoplasmic reticulum (ER) to Golgi vesicle-mediated transportIntracellular protein transportMaintenance of Golgi apparatus structureChoice and formation of transport vesicles (COPI/COPII interaction)
04

Disease associations

Cancer (notably hepatocellular carcinoma, cervical cancer, bladder cancer)Hereditary essential tremor (rare association)
05

Safety considerations

No notable drug-related safety concerns directly established; as TMED5 is key to vesicle trafficking and Golgi structure, off-target inhibition could theoretically impact numerous cellular transport processes
06

Interacting drugs

None currently known or clinically established
07

Biomarkers

Potential for use of TMED5 expression as a biomarker for hepatocellular carcinoma, cervical cancer, and poor prognosis in cancer

Beyond the preview

Go deeper on Transmembrane emp24 domain-containing protein 5 (TMED5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transmembrane emp24 domain-containing protein 5 (TMED5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call